NICE announces interventional procedure guidance supporting use of hydrogel spacer in treatment of prostate cancer in the UK

A medical technology company that develops, manufactures, and sells proprietary absorbable hydrogels that separate and protect organs at risk during radiotherapy, today announced that the National Institute for Health and Care Excellence (NICE) in the UK has issued Interventional Procedure Guidance supporting the use of a hydrogel barrier to reduce the risk of toxicity to surrounding tissue in radiotherapy to treat prostate cancer.
Business Wire